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Durable natural killer cell responses after heterologous two-
dose Ebola vaccination
Helen R. Wagstaffe1,7, Giada Susannini1, Rodolphe Thiébaut2,3, Laura Richert2,3, Yves Lévy 4, Viki Bockstal5, Jeroen N. Stoop5,
Kerstin Luhn5, Macaya Douoguih5, Eleanor M. Riley 1,6, Christine Lacabaratz 4 and Martin R. Goodier 1✉
Natural killer (NK) cells are implicated among immune effectors after vaccination against viral pathogens, including Ebola virus. The
two-dose heterologous Ebola virus vaccine regimen, adenovirus type 26.ZEBOV followed by modified vaccinia Ankara-BN-Filo
(EBOVAC2 consortium, EU Innovative Medicines Initiative), induces NK cell activation and anti-Ebola glycoprotein (GP) antibody-
dependent NK cell activation post-dose 1, which is further elevated post-dose 2. Here, in a multicentre, phase 2 clinical trial
(EBL2001), we demonstrate durable ex vivo NK cell activation 180 days after dose 2, with responses enriched in CD56bright NK cells.
In vitro antibody-dependent responses to immobilised Ebola GP increased after dose 1, and remained elevated compared to pre-
vaccination levels in serum collected 180 days later. Peak NK cell responses were observed post-dose 2 and NK cell IFN-γ responses
remained significantly elevated at 180 days post-dose 2. Individual variation in NK cell responses were influenced by both anti-
Ebola GP antibody concentrations and intrinsic interindividual differences in NK cell functional capacity. In summary, this study
demonstrates durable NK cell responses after Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccination and could inform the
immunological evaluation of future iterations of the vaccine regimen and vaccination schedules.
npj Vaccines            (2021) 6:19 ; https://doi.org/10.1038/s41541-021-00280-0
INTRODUCTION
Adenovirus type 26 (Ad26).ZEBOV, modified vaccinia Ankara
(MVA)-BN-Filo is a safe and immunogenic, two dose anti-Ebola
vaccine regimen that recently received marketing authorisation
approval under exceptional circumstances by the European
Medicines Agency (EMA)1–5. Ebola virus infection continues to
be a significant global health concern with ongoing outbreaks on
the African continent6; the need for further understanding of
protective immunity induced by currently licensed vaccines
against Ebola virus infection is ever more pressing.
Ebola virus glycoprotein (GP), expressed on the surface of the
mature virus particle, is a highly immunogenic antigen. Stimula-
tion of human PBMC with Ebola GP (EBOV GP) in vitro induces the
secretion of high levels of pro and anti-inflammatory cytokines
including IL-10, GM-CSF, IL-1β, and TNFα and lower levels of IL-12,
IL-18, and type I IFN7–13. We and others demonstrated a
dependence on accessory cell TLR-4 engagement for the
stimulatory effects of EBOV GP in vitro7,10,12,13. Further, we
provided evidence that IL-12 and IL-18 secretion in response to
EBOV GP leads to NK cell activation within whole human PBMC
cultures, independent of Ebola vaccination status. However, IL-10
impairs NK cell activation (in particular IFN-γ secretion), suggesting
that the mixed cytokine response to EBOV GP may limit NK cell
activation13. Ad26.ZEBOV, MVA-BN-Filo vaccination induces a
proliferative increase in less differentiated NK cells up to 21 days
post-dose 2, accompanied by an increased frequency of CD25+ NK
cells, suggesting an increased responsiveness to CD4+ T cell
derived IL-213.
Anti-Ebola antibodies induce NK cell antibody-dependent
cellular cytotoxicity (ADCC) in human PBMC in vitro and contribute
to protection against EVD14–17. Our previous studies show that
serum collected post-dose 1 and post-dose 2 from Ad26.ZEBOV,
MVA-BN-Filo vaccinated individuals induced significant NK cell
degranulation (surface expression of CD107a), higher IFN-γ
secretion and CD16 (FcγRIII) downregulation compared with
baseline (pre-vaccination) serum18.
We performed an exploratory, post-hoc evaluation of the
magnitude and durability of ex vivo NK cell phenotypic changes
and in vitro EBOV GP-dependent NK cell responses in samples
from a phase 2 clinical trial of the Ad26.ZEBOV, MVA-BN-Filo
vaccine. The original trial incorporates three arms with varying
time intervals (28, 56, or 84 days) between dose 1 (Ad26.ZEBOV)
and dose 2 (MVA-BN-Filo). We demonstrate prolonged alterations
in ex vivo NK cell phenotype with evidence of functional
activation (CD25 expression) up to 180 days post-dose 2 after
Ad26.ZEBOV, MVA-BN-Filo vaccination. Furthermore, EBOV GP
specific serum antibodies from vaccinated subjects supported
durable NK cell function up to 180 days after vaccination.
NK cell responses were highly variable between individuals
(even in the presence of a fixed concentration of a standard post-
vaccination serum) and were enriched in CD56dimCD57+ (more
differentiated) NK cells, indicating an effect of both antibody
concentration and individual NK cell differentiation status on
antibody-driven NK cell effector function. In line with previous
reports, infection with human cytomegalovirus (HCMV)—which
induces the expansion of highly differentiated CD57+ and
NKG2C+ NK cell populations with an “adaptive” (FcεR1γ−)
phenotype and specialised towards antibody-dependent
responses19,20—was a significant modifier of the ADCC response
to EBOV GP.
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In summary, NK cell responses may contribute to durable
immune protection of target populations receiving the Ad26.
ZEBOV, MVA-BN-Filo vaccine.
RESULTS
NK cell phenotypic changes after Ad26.ZEBOV, MVA-BN-Filo
vaccination are sustained at day 180 post-dose 2
Previously, we demonstrated NK cell activation (CD25/IL-2Ra
expression) accompanied by proliferation (Ki67 expression) of less
differentiated (CD56bright and CD56dimCD57−) NK cell subsets up to
21 days after dose 2 of Ad26.ZEBOV, MVA-BN-Filo vaccination13. In
this current study, we analyse the effect of Ad26.ZEBOV, MVA-BN-
Filo vaccination on NK cell phenotype and activation in a
multicentre, phase 2 randomised clinical trial (EBL2001) up to
180 days post-dose 2. PBMC-derived CD56+CD3− NK cells from
baseline (day 1; visit 0, which corresponds to administration of
dose 1), day 29, 57, or 85 post-dose 1 (visit 1, which corresponds to
administration of dose 2), 14 days post-dose 2 (visit 2) and
180 days post-dose 2 (visit 3) were analysed by flow cytometry. Ex
vivo CD25 and Ki67 expression were measured within gated NK
cells (gating strategy is shown in Supplementary Fig. 1a, b). Less
differentiated (CD57−), total adaptive (NKG2C+ or FcεR1γ− cells)
and highly differentiated CD57/NKG2C and CD57/FcεR1γ defined
subsets were measured within the CD56dim NK cell subset (gating
strategy is shown in Supplementary Fig. 1c).
Initially, data from all participants from all groups receiving
active vaccination were combined for analysis (see Table 1 for
participant numbers). Other than a significant difference in the
frequencies of CD56bright NK cells comparing baseline to 180 days
post-dose 2, there was no significant difference in the frequencies
of CD56dim, CD25+, or Ki67+ NK cells between vaccination visits
(one-way ANOVA mixed effects analysis with Geisser–Greenhouse
correction was used due to missing data caused by an
unanticipated pause in the clinical trial) (Supplementary Fig.
2a–d). Similarly, there were no significant effects of vaccination on
the frequencies of highly differentiated or adaptive NK cell subsets
defined by the markers CD57, NKG2C, or FcεR1γ, either alone or in
combination (Supplementary Fig. 2e–i). However, considerable
variation between individuals in their NK cell profiles at baseline
(visit 0) and at all subsequent visits limited the power of this
analysis. We therefore analysed paired PBMC samples collected
Table 1. Randomised vaccination regimen and corresponding numbers of serum and PBMC samples used in this study.
Group Vaccine schedule Timing of samples used in this study (n= serum/PBMC)
Baseline (Visit 0) Post-dose 1 (Visit 1) 14 days post-dose 2 (Visit 2) 180 days post-dose 2 (Visit 3)
1 Ad26a, MVAb Day 1 (26/12) Day 29 (27/7) Day 43 (27/15) Day 209 (26/11)
2 Ad26, MVA Day 1 (26/6) Day 57 (26/8) Day 71 (26/19) Day 237 (24/13)
3 Ad26, MVA Day 1 (12/4) Day 85 (12/5) Day 99 (12/8) Day 265 (12/10)
Study participants received monovalent Ad26.ZEBOV expressing the GP of the Ebola Zaire virus (Mayinga variant) followed by multivalent MVA-BN-Filo
expressing the GP of the Sudan and Zaire Ebola viruses and Marburg virus together with Tai Forest virus nucleoprotein. Groups 1, 2, and 3 received Ad26.
ZEBOV on day 1 and MVA-BN-Filo on day 29, 57, or 85 respectively.
aAdenovirus type 26.ZEBOV.
bModified vaccinia Ankara-BN-Filo.
Fig. 1 Ex vivo analysis of NK cell subsets and activation markers. Frequencies of CD56bright (a), CD56dim (b), CD25 (c), and Ki67 (d)
expressing NK cells and frequencies of CD57−(e), NKG2C+(f), FcεR1γ−(g), CD57/NKG2C (h), and CD57/FcεR1γ (i) defined subsets within
CD56dim NK cells, between visit 0 (baseline) and visit 3 (180 days post-dose 2). Vaccination groups were pooled for analysis. Paired data points
are shown for individual study participants as before and after plots (n= 10). Comparisons were made using Wilcoxon signed-rank test. *p <
0.05, **p < 0.01.
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from individual vaccinees at baseline (visit 0) and day 180 post-
dose 2 (visit 3) (n= 10).
In this paired analysis (Fig. 1), CD56bright NK cell frequencies were
significantly elevated at 180 days post-dose 2 compared with
baseline (Fig. 1a) and CD56dim NK cell frequency was significantly
decreased at day 180 post-dose 2 compared with baseline (Fig. 1b).
The frequency of CD25+ NK cells was also significantly increased at
day 180 post-dose 2 (Fig. 1c), although the difference in Ki67
expression did not reach statistical significance (Fig. 1d). No
significant changes were observed comparing baseline and day
180 post-dose 2 frequencies of more differentiated NK cell subsets,
including CD56dim CD57−, NKG2C+, FcεR1γ−, and subsets defined
by differing combinations of CD57, NKG2C, or FcεR1γ (Fig. 1e–i). In
all paired comparisons between visits other than visit 0 vs. visit 3
(Supplementary Table 1), only the frequency of CD56dim NK cells
was significantly lower at visit 3 compared with visit 1 (p= 0.018),
consistent with the difference compared to baseline values.
The NK cell response within each vaccination group (groups
1, 2, and 3; received Ad26.ZEBOV on day 1 and MVA-BN-Filo on
days 29, 57, or 85 respectively, details of vaccine dosing
intervals for each vaccine group are given in Table 1 and in the
“Materials and methods” section) was analysed to test whether
the interval between vaccine doses impacted on NK cell
phenotype and activation (Supplementary Fig. 3a–d). A
significant increase in frequency of less differentiated CD56bright
NK cells (Supplementary Fig. 3a), and a reciprocal decrease in
representation of CD56dim NK cells (Supplementary Fig. 3b) was
observed across visits in group 1 (28-day interval), with a non-
significant trend in group 3 (84-day interval). Groups 1 and 3
also demonstrated a trend towards increasing frequencies of
CD25 expression after vaccination (Supplementary Fig. 3c),
although no significant change in Ki67 expression was observed
across the vaccination time course (Supplementary Fig. 3d).
These data are consistent with effects on less differentiated NK
cells after Ad26.ZEBOV, MVA-BN-Filo vaccination at day 180
post-dose 2 without substantial differences according to the
interval between vaccine doses.
Fig. 2 Durable antibody-dependent NK cell responses to immobilised EBOV GP. CD107a (a, d), CD16 MFI (b, e), and IFN-γ (c, f) expression
among NK cells from a standard PBMC population (from a single unvaccinated donor) cultured with serum samples from individual trial donors
collected pre-vaccination (visit 0), on day 29, 57 or 85 post-dose 1 (visit 1), 14 days post-dose 2 (visit 2) and 180 days post-dose 2 (visit 3). Data
are shown for all vaccination groups combined (a–c) and by individual vaccination group (d–f) (see Table 1 for number of participants). Plots
show mean values with standard error of the mean (s.e.m.). Across visit (a–c) and intergroup (d–f) comparisons were performed using one-way
ANOVA mixed effects analysis with Geisser–Greenhouse correction. *p < 0.05, ***p < 0.001, ****p < 0.0001.
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Maintenance of post-Ad26.ZEBOV, MVA-BN-Filo vaccination-
induced antibody-dependent NK cell activation at 180 days
post-dose 2
We measured antibody-dependent NK cell activation (CD107a,
IFN-γ induction, and downregulation of CD16; gating strategy
shown in Supplementary Fig. 4), in response to baseline (visit 0),
post-dose 1 (visit 1), 14 days post-dose 2 (visit 2), and 180 days
post-dose 2 (visit 3) serum plus immobilised EBOV GP using a
uniform responder NK cell preparation (whole PBMC from one
non-vaccinated, locally-recruited blood donor).
When data from all three vaccination groups were combined for
analysis, there was a significant induction of CD107a expression
and IFN-γ secretion, and a significant downregulation of CD16
expression (MFI) on CD56dim NK cells in response to stimulation
with EBOV GP in the presence of post-dose 1 (visit 1) and 14 day
post-dose 2 (visit 2) serum compared with baseline serum (Fig.
2a–c). Serum from day 180 post-dose 2 (visit 3) induced a
significant increase in NK cell CD107a and IFN-γ expression
frequencies compared with baseline, suggesting the response is
maintained at this later time point. Day 180 NK cell responses
were, however, significantly lower than those observed at 14 days
post-dose 2 (visit 2), suggesting a decline in antibody-driven NK
cell function over time (Fig. 2a, c). Consistent with a gradual
decline in antibody-mediated NK cell responses, CD16 expression
returned to near baseline levels by day 180 post-dose 2, indicating
more limited antibody-FcR interaction (Fig. 2b).
A trend for increasing NK cell CD107a and IFN-γ expression
and CD16 downregulation in response to EBOV GP and post-
vaccination serum peaking at visit 2 and reducing by visit 3 was
evident in all three vaccination groups (Fig. 2d–f). Functional
responses were significantly higher in the presence of visit
2 serum compared to baseline (visit 0) and remained above
baseline at day 180 post-dose 2 (visit 3), in all vaccination
groups (Table 2). A modest, but statistically significant, increase
in the frequency of CD107a+ NK cells was observed in group 3
compared with group 1 at visit 2 (p= 0.016; Fig. 2d) and CD16
MFI was marginally lower in group 3 compared with group 1 at
visit 3 (p= 0.046; Fig. 2e), consistent with a longer interval
between the two vaccine doses promoting stronger NK cell
responses. These data are consistent with the geometric mean
antibody concentrations (GMC) measured for each group post-
dose 2 (Group 1, GMC= 3888 units/ml, 95% CI= 2375–6364;
Group 2, GMC= 8346 units/ml, 95% CI= 6207–11,224; and
Group 3, GMC= 9624, 95% CI 6843–13,535).
Similar patterns of antibody-dependent NK cell responses were
observed when these responses were analysed according to each
NK cell differentiation subset (Fig. 3). For these experiments, cells
from a single standard NK cell donor were used to minimise
effects of NK cell variation and allow the effects of varying
antibody responses to be elucidated. The NK cell donor was
specifically selected to have a balanced distribution of NK cell
differentiation subsets (CD56bright, 4.9%; CD56dimCD57−, 39.1%;
CD57+NKG2C−, 26.3% and CD57+NKG2C+, 29.6%). CD107a
expression was upregulated and peaked at visit 2 in both
CD56bright and CD56dim subsets (Fig. 3a). Reciprocal downregula-
tion of CD16 was also observed in all NK cell subsets analysed,
with CD56dimCD57+ (NKG2C− and NKG2C+) subsets expressing
the highest levels of this Fc receptor both at baseline and after
vaccination (Fig. 3b). IFN-γ upregulation was restricted to CD56dim
subsets (Fig. 3c), which was confirmed by back-gating analysis
showing 53.2% of CD107a+ and 75.1% of IFN-γ+ NK cells were
CD56dimCD57+ cells (both NKG2C+ and NKG2C−) (Fig. 3d).
CD56dim CD107a and IFN-γ responses were significantly higher
at day 180 post-dose 2 compared with baseline, but significantly
lower compared with visit 2 (Fig. 3a, c). This demonstrates a
stronger antibody-dependent response within more differentiated
cells, which is maintained at 180 days post-dose 2.
Differential NK cell response between multiple vaccinated
individuals in response to both autologous and pooled post-
vaccination serum
We next investigated the extent to which variation in antibody
concentration combined with intrinsic differences in NK cell
functional capacity influenced NK cell function in response to
EBOV GP in vaccinated individuals. We analysed antibody-
dependent responses of NK cells (within PBMC collected at visits
0, 1, 2, and 3 from trial Ad26.ZEBOV, MVA-BN-Filo vaccinated
individuals) when restimulated in vitro with EBOV GP in the
presence of autologous serum collected at the same visit and, as a
control, visit 2 NK cells from each subject cultured with EBOV GP
and a standardised post-vaccination serum from visit 2 (pooled
from all study individuals).
Consistent with the response kinetics observed for a
standardised NK cell readout, median frequencies of CD107a+
and IFN-γ+ NK cells increased significantly in response to
autologous visit 2 serum compared with visit 1 serum. Moreover,
the frequency of IFN-γ expressing cells remained elevated (i.e.,
above visit 1) at visit 3 (Fig. 4a, c). Consistent with the observed
changes in NK cell function after vaccination, the median MFI
value for CD16 was significantly lower at visits 2 and 3 compared
with baseline (Fig. 4b).
To investigate the impact of intrinsic variation within the NK cell
population we also analysed individual level NK cell responses to
EBOV GP plus visit 2 (peak response) serum pooled from all trial
donors (visit 2 pool; V2p). In the presence of V2p serum, there was
Table 2. Summary statistics for anti-EBOV GP-dependent NK cell
activation.
Group Visita p valueb
CD107a (%) CD16 (MFI) IFN-γ (%)
1 0 vs. 1 0.003 0.005 0.034
0 vs. 2 <0.0001 <0.0001 <0.0001
0 vs. 3 0.731c 0.978c 0.377c
1 vs. 2 0.335c 0.033 0.012
1 vs. 3 0.055c 0.019 0.685c
2 vs. 3 0.0004 <0.0001 0.001
2 0 vs. 1 0.002 0.002 0.040
0 vs. 2 <0.0001 <0.0001 <0.0001
0 vs. 3 0.001 0.216c 0.021
1 vs. 2 <0.0001 <0.0001 0.000
1 vs. 3 0.998c 0.298c 0.987c
2 vs. 3 <0.0001 <0.0001 0.001
3 0 vs. 1 0.639c 0.725c 0.166c
0 vs. 2 0.001 <0.0001 <0.0001
0 vs. 3 0.534c 0.579c 0.125c
1 vs. 2 0.011 <0.0001 0.001
1 vs. 3 0.998c 0.995c 0.999c
2 vs. 3 0.017 <0.0001 0.001
NK cell CD107a, CD16, and IFN-γ expression in whole PBMC from a single,
unvaccinated donor across the course of vaccination according to
vaccination group (in relation to Fig. 2).
IFN interferon, MFI mean fluorescence intensity.
aVisit 0 = pre-vaccination; visit 1 = day 29 (group 1), 57 (group 2) or 85
(group 3) post-dose 1; visit 2= 14 days post-dose 2; visit 3= 180 days post-
dose 2.
bOne-way ANOVA mixed effects model with Geisser–Greenhouse correc-
tion. Significance was defined as p < 0.05.
cns non-significant.
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a significant induction of CD107a and IFN-γ over visit 1 and CD16
was significantly downregulated compared with baseline. Inter-
estingly, there was no significant difference in NK cell response
between visit 2 autologous serum (with varying antibody
concentration) and V2p serum (constant antibody concentration)
measured by one-way ANOVA (Fig. 4a–c). Moreover, the
magnitude of the NK cell response of vaccinated donors was
similar whether they were incubated in their own serum or the
pooled V2p serum suggesting that variation was not driven by
antibody concentration alone. This suggests that interdonor
variation in NK cell phenotype is a driver of interindividual
variation in antibody-dependent NK cell function.
When data were analysed by vaccination group, cells, and
serum from group 3 tended to show stronger responses than
those from group 1 and 2 (non-significant), with maximal
responses seen at visit 2 (non-significant), however, low numbers
of matched samples precluded robust statistical comparison
between time points and groups (Fig. 4d–f).
The frequencies of responding cells were then analysed within
NK cell differentiation subsets (Fig. 5). Consistent with data
obtained from the use of a single standardised NK cell readout,
the majority of CD107a+ were CD56dimCD57− and CD56dimCD57+
(Fig. 5a, d), the baseline expression of CD16 increasing with higher
differentiation from CD56dimCD57− to CD56dimCD57+ (NKG2C−
or NKG2C+) and being reduced to similar levels across all subsets
and IFN-γ+ production being enriched in the most highly
differentiated CD56dimCD57+ subsets, irrespective of NKG2C
expression (Fig. 5c, d).
Antibody-dependent responses of HCMV seropositive
individuals with NKG2C+CD57+ NK cell expansions
We observed a wide distribution of antibody-dependent NK cell
responses with many individuals having little or no response to
EBOV GP even within CD57+ and CD57+NKG2C+ subsets (Fig. 5)
and considered that HCMV infection may confound this analy-
sis19,20. Accordingly, HCMV seropositive individuals had signifi-
cantly higher frequencies of CD56dimCD57+NKG2C+ NK cells post-
dose 2 when compared with the seronegative individuals (Fig. 6a).
Comparison of antibody dependent responses after dose 2
revealed that CD107a responses were significantly reduced in
HCMV seropositive individuals with low frequencies of (<5% of
CD56dim NK cells) CD56dimCD57+NKG2C+ cells compared to
HCMV seronegative individuals, and a with a reduced median
response compared to HCMV seropositive individuals with higher
frequencies (>5% of CD56dim NK cells) of these adaptive cells
(Fig. 6b). No significant difference was observed in IFN-γ
production between these groups of individuals (Fig. 6c). These
data suggest that individual level variation in the adaptive NK cell
compartment, and differences in HCMV infection rates between
populations may influence antibody dependent NK cell responses
after vaccination.
Individual level relationship between anti-Ebola glycoprotein
antibody concentration and NK cell responses
Assays using a standard NK cell readout (PBMC from a single
donor) to test the NK cell activating potential of post-vaccination
Fig. 3 Antibody-dependent responses of different NK cells subsets. NK cells from a single unvaccinated donor were cultured with EBOV GP
in the presence of serum collected from pre-vaccination (visit 0), on day 29, 57, or 85 post-dose 1 (visit 1), 14 days post-dose 2 (visit 2) and
180 days post-dose 2 (visit 3) and analysed by flow cytometry for CD107a (a), CD16 MFI (b), and IFN-γ (c) expression according to NK cell
differentiation subset. Data are pooled for all three vaccine groups (see Table 1 for n). Data points are shown with bars representing median
values. The proportion of total NK cell CD107a and IFN-γ expression (using visit 2 serum) attributed to each subset is shown as a pie chart (d),
with each slice representing the median (see Table 1 for number of participants). Comparisons across visits were performed using one-way
ANOVA mixed effects analysis with Geisser–Greenhouse correction and comparison between subsets was performed using and one-way
ANOVA with Dunn’s correction. ****p < 0.0001.
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serum from all vaccinated individuals demonstrate variation, that
may be due to differences in antibody concentration. Assays using
a standardised serum to test cells from multiple donors also
revealed an impact of individual differences in NK cell function. In
an effort to determine whether inherent variation in NK cell
function or differences in post-vaccination antibody titres, or both,
are drivers of inter-individual variation we looked for correlations
between the NK cell response and antibody concentration. We
correlated NK cell functional data from the single (unvaccinated)
donor or individual trial donors in the presence of individual post-
vaccination (visit 2) serum with antibody concentration.
The NK cell function of the single non-vaccinated donor in
response to EBOV GP and multiple trial serum samples from visit 2
correlated weakly with the anti-GP antibody concentration
determined for each sample used (Fig. 7). CD16 MFI was
significantly negatively correlated with antibody concentration
(Fig. 7b), whereas CD107a and IFN-γ show non-significant, weak
positive correlations (Fig. 7a, c). When each vaccination group was
analysed separately, significant correlations between NK cell
function and antibody concentration were observed only in group
2 (Table 3). The NK cell function of multiple trial individuals in
response to EBOV GP and autologous serum from visit 2 did not
correlate with antibody concentration determined for each
sample when all groups were combined (Fig. 7d–f) or when
analysed according to vaccination group (Table 3). These data
suggest antibody concentration, the composition of the NK cell
compartment and other, unidentified, NK cell-intrinsic factors may
all affect antibody-induced NK cell function.
DISCUSSION
Previous clinical studies of the Ad26.ZEBOV, MVA-BN-Filo vaccine
regimen have shown that Ad26.ZEBOV administration followed by
boosting with MVA-BN-Filo, induces high initial EBOV GP-specific
antibody responses1,2,5. In this study, we assessed the magnitude
and durability (upto 180 days post-dose 2) of changes in NK cell
phenotype and function measured both ex vivo and after in vitro
restimulation with EBOV GP after Ad26.ZEBOV, MVA-BN-Filo
vaccination. We provide evidence of sustained enhancement of
NK cell function—both ex vivo and in vitro—after Ad26.ZEBOV,
MVA-BN-Filo Ebola vaccination suggesting that these cells could
potentially contribute to both immediate and long-lasting
vaccine-induced immunity to Ebola virus infection.
Ad26.ZEBOV, MVA-BN-Filo vaccination induced a persistent (at
least 180 days post-dose 2) increase in the ex vivo proportion of
CD56bright NK cells but there was no significant change in the
frequencies of more differentiated, adaptive subsets
(CD56dimCD57+ NKG2C+ and FcεR1γ−). These data are consistent
with constitutive expression by CD56bright NK cell of receptors for
activating cytokines, including for the myeloid lineage derived
cytokines IL-12 and IL-1821–23, that are induced by Ebola
vaccination9,10. The subsequent upregulation of CD25 (IL-2Rα)
confers high affinity for T cell-derived IL-2, stimulating them to
proliferate (and thus expression of Ki67)24,25. Activation and
proliferation of CD56bright NK cells has previously been reported as
a feature of whole organism or live-attenuated vaccines24–29, and
is line with our previous observations with this vectored vaccine
including secretion of NK cell activating cytokines in supernatants
of EBOV GP stimulated PBMC13. Recent studies, published in this
journal, demonstrate dose-dependent increases in NK cell
numbers and functional modulation within days of live attenuated
rVSV-ZEBOV vectored vaccination30. The longer-term effects
observed here are consistent with the rapid proliferation and
relatively long lifespan of CD56bright NK cells31. Activated
CD56bright NK cells migrate to secondary lymphoid tissues and,
through the production of IFN-γ, contribute to priming of adaptive
immune responses and recruitment of effector cells during the
vaccine response32–34.
Fig. 4 Antibody-dependent responses of NK cells from individual trial participants using their autologous pre-vaccination and post-
vaccination sera. PBMCs collected pre-vaccination (visit 0), post-dose 1 (visit 1), 14 days post-dose 2 (visit 2), and 180 days post-dose 2 (visit 3)
were cultured with EBOV GP in the presence of autologous serum from the same visit (or pooled visit 2 serum; V2p) and analysed by flow
cytometry for CD107a (a, d), CD16 MFI (b, e), and IFN-γ (c, f) expression. Pooled data from all three vaccine groups (see Table 1 for number of
participants), data points are shown with a line representing median values (a–c). Data according to individual vaccination groups are shown
with mean values and s.e.m. Comparisons between visit was performed using one-way ANOVA mixed effects analysis with Geisser–Greenhouse
correction. *p < 0.05, **p < 0.01, ***p < 0.001.
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This study also demonstrates a major role for EBOV GP-specific
antibody in activation of NK cells after Ad26.ZEBOV, MVA-BN-Filo
vaccination with robust and durable antibody-dependent NK cell
responses detectable for at least 180 days after the second dose in
most individuals. Although not entirely consistent between the
different measures of the response, a vaccination schedule in
which dose 2 is given either 56 or 84 days after the first dose
(rather than 28 days) tended to induce stronger and more durable
antibody-dependent NK cell responses. This is in line with the
benefits of delaying the second dose on immunogenicity in other
trials of this two dose Ad26.ZEBOV, MVA-BN-Filo vaccine
regimen1,2,5.
Variation between individuals in their post-vaccination anti-
body-dependent NK cell response reflects individual variations in
antibody responses to the vaccine, in the strength of individuals’
innate cytokine responses and variations in their pre-existing NK
cell populations. High resolution analysis of human peripheral
blood NK cells has revealed considerable inter-individual diversity
in NK cell clones that is both genetically determined35 and
influenced by prior infection history, especially infection with
human cytomegalovirus19,20,36. Importantly, age-related and
infection-induced differentiation of human NK cells results in
progressive loss of cytokine-responsive cells and concomitant
accumulation of cells that are highly adapted to activation by
immune complexes (termed “adaptive” CD57+NKG2C+ or
CD57+FcεRγ− NK cells), suggesting that the response to
vaccination may vary with age and environmental exposures to
infection, in particular human cytomegalovirus19,20. Indeed, we
detected considerable variation in the baseline frequencies of
“adaptive” CD57+NKG2C+ or CD57+FcεR1γ− NK cell subsets
among the study cohort and observed that CD57+NKG2C+ cells
make an increased contribution to anti-EBOV GP antibody
dependent IFN-γ responses in HCMV seropositive compared to
HCMV seronegative individuals. In the context of individual
variation in NK cell responses, one caveat of these studies is that
they are conducted with a relatively small, highly selected,
European group of heathy volunteers which may not directly
reflect the responses observed in a more heterogeneous
population in an Ebola endemic area. Planned future studies in
African vaccination cohorts will begin to address this issue.
In summary, this study demonstrates robust, durable, antibody-
dependent NK cell responses to Ad26.ZEBOV, MVA-BN-Filo Ebola
virus vaccination and could inform immunological evaluation of
future iterations of the vaccine regimen and vaccination
schedules.
METHODS
Study participants and samples
Eligible, healthy adult volunteers were recruited into a multi-centre,
randomised, placebo-controlled, observer blind Ebola vaccine trial, held
in Europe; EBL2001 (ClinicalTrials.gov Identifier NCT02416453;
Fig. 5 Subset distribution of antibody-dependent responses induced in multiple NK cell donors and autologous pre/post-vaccination
serum. Trial participant NK cell CD107a (a), CD16 MFI (b), and IFN-γ (c) expression in response to autologous pre-vaccination (visit 0), post-
dose 1 (visit 1), 14 days post-dose 2 (visit 2) and 180 days post-dose 2 (visit 3) serum for all vaccine arms combined were analysed according to
NK cell differentiation subset. Data are pooled for all three vaccine groups (see Table 1 for number of participants), data points are shown with
a line representing median values. The proportion of total NK cell CD107a and IFN-γ expression (visit 2) attributed to each subset is shown as a
pie graph, with each slice representing the median (d). Comparisons across visits were performed using one-way ANOVA mixed effects
analysis with Geisser–Greenhouse correction and comparison between subsets was performed using one-way ANOVA with Dunn’s correction.
*p < 0.05, **p < 0.01, ***p < 0.001.
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registered 15th April 2015, https://clinicaltrials.gov/ct2/show/NCT024
16453?term=VAC52150EBL2001&draw=2&rank=2). Active vaccination
comprised monovalent Ad26.ZEBOV expressing the GP of the Ebola
Zaire virus (Mayinga variant) followed by multivalent MVA-BN-Filo
expressing the GP of the Sudan and Zaire Ebola viruses and Marburg
virus together with Tai Forest virus nucleoprotein (Janssen Vaccines and
Prevention B.V., The Netherlands and Bavarian Nordic, Denmark).
Groups 1, 2, and 3 received Ad26.ZEBOV on day 1 and MVA-BN-Filo
on day 29, 57, or 85 respectively.
Serum and PBMC samples were collected at baseline (visit 0), post-dose
1 (day of dose 2 administration, day 29, 57, and 85 respectively; (visit 1),
14 days post-dose 2 (visit 2) and 180 days post-dose 2 (visit 3). Samples
from 59 actively vaccinated donors (i.e., non-placebo arm) aged between
21 and 62 years were analysed for this study (Table 1). Additional whole
blood samples were obtained from non-vaccinated, non-study volunteers
from among staff and students of The London School of Hygiene &
Tropical Medicine (LSHTM). The EBL2001 trial protocol and study
documents were approved in France by the French national Ethics
Committee “CPP Ile de France III” (reference number 3287) and the French
Medicine Agency (ANSM) (reference number 150646A-61) and in the UK by
the Medicines and Healthcare Products Regulatory Agency (MHRA) and
National Research Ethics Service (Reference South Central—Oxford A 15/
SC/0211) and the LSHTM Research Ethics Committee (reference number
14760). All participants of the EBL2001 trial provided written informed
consent.
PBMC from non-vaccinated non-trial volunteers were isolated using
Histopaque 1077 gradient centrifugation and cryopreserved in liquid
nitrogen or used immediately. PBMC from EBL2001 volunteers from France
were isolated using Leucosep tubes, cryopreserved in liquid nitrogen and
shipped to LSHTM. EBOV GP-specific IgG concentration was determined by
Fig. 6 Distribution of NK cell responses in HCMV seropositive individuals. Frequencies of highly differentiated NK cells
(CD56dimCD57+NKG2C+) in samples from HCMV seronegative (n= 12) and HCMV seropositive (n= 21) individuals post vaccine dose 2 in
this cohort (a). CD107a (b) and IFN-γ (c) responses of CD56dim NK cells HCMV seronegative (open circles) and HCMV seropositive individuals
with low (<5%, black circles) and higher (>5%, grey circles) frequencies of adaptive (CD57+NKG2C+ NK cells after vaccine dose 2. Comparisons
were made using Mann–Whitney U-test. **p < 0.01; *p < 0.01.
Fig. 7 Correlation between vaccination-induced anti-GP antibody concentration and NK cell responses. PBMC from a single unvaccinated
donor (a–c) or from individual study participants at visit 2 (d, e) were cultured with EBOV GP in the presence of serum collected from the trial
individuals 14 days post-dose 2 (visit 2). NK cell CD107a (a, d), CD16 MFI (b, e), and IFN-γ (c, f) expression was compared with anti-GP antibody
concentration (measured at visit 2) (ELISA units/ml; determined previously38 (see Table 1 for number of participants). Goodness-of-fit line was
determined by linear regression and r and p-value analysis was performed by Pearson correlation, significance was defined as p < 0.05.
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the EBOV GP Filovirus Animal Non-Clinical Group (FANG) ELISA37. Human
cytomegalovirus (HCMV) serostatus was determined by IgG ELISA (Deme-
ditec, Kassel, Germany) (59% of study subjects were HCMV seropositive).
NK cell assays
Cryopreserved PBMCs were thawed, washed in RPMI 1640 supplemented
with 100U/ml penicillin/streptomycin and 20 mM L-glutamine (Gibco,
ThermoFisher), counted using Countess II FL Automated Cell Counter
(Invitrogen, ThermoFisher) and rested for 2 h. The average cell yield after
thaw was 3.0 × 106 per vial. Study PBMC were either stained immediately
ex vivo or were cultured in 96-well round-bottom plates in RPMI
1640 supplemented as above. 10 μg/ml purified recombinant Ebola virus
GP (EBOV GP; Mayinga variant, prepared in Hek293F cells; Janssen Vaccines
and Prevention B.V.) was immobilised on 96-well flat bottom tissue culture
plates overnight at 4 °C. Plates were washed, blocked with 5% FCS (Gibco,
ThermoFisher) in RPMI 1640 supplemented as above for 30min and
washed again. PBMC from a single, non-study donor (non-vaccinated; from
fresh blood) or from vaccinated EBL2001 trial participants (cryopreserved)
were washed in RPMI 1640 supplemented as above. PBMC were seeded
(3 × 105/well) onto the antigen-coated plates together with pre or post-
vaccination serum (autologous in the case of vaccine study PBMC) or
pooled visit 2 serum at 5% and incubated for 6 hours at 37 °C. GolgiPlug
(Brefeldin A; 1/1000 final concentration; BD Biosciences) and GolgiStop
(Monensin; 1/1500 concentration; BD Biosciences) were added for the final
3 h of culture. Cells were harvested into round-bottom plates by soaking
and resuspension in cold PBS (containing 0.5% FCS, 0.05% sodium azide,
and 2mM EDTA) for staining.
Flow cytometry
Anti-CD107a-FITC (clone H4A3; BD Biosciences) was added to the cultures
(2 µl per well) for the entire culture period. Cells were stained for all other
surface markers including a viability marker (Fixable Viability Stain 700; BD
Biosciences) in FACS buffer (PBS, 0.5% FCS, 0.05% sodium azide and 2mM
EDTA) for 30min in 96-well round bottom plates after blocking Fc
receptors for 5 min with Fc Receptor (FcR) Blocking Reagent (Miltenyi
Biotec). Cells were then washed in FACS buffer, fixed and permeabilised
using Cytofix/Cytoperm Kit (BD Biosciences) or Foxp3/Transcription Factor
Fixation/Permeabilisation Kit (eBiosciences) according to the manufac-
turer’s instructions. Cells were then stained for intracellular markers with
FcR blocking for 20min and washed again. Finally, cells were resuspended
in FACS buffer and analysed using a BD LSRII flow cytometer. Cells were
acquired using FACSDiva software and data were analysed using FlowJo
V10 (Tree Star, Oregon, USA). FACS gates were set using unstimulated cells
or FMO controls. Samples with less than 100 NK cell events were excluded
from the analysis (less than 3% of samples).
The following antibodies were used: anti-CD3-V500 (clone UCHT1) (BD
Biosciences), anti-CD56-BV605 (clone HCD56), anti-IFN-γ-BV785 (clone 4S.
B3), anti-CD25-BV785 (clone BC96) (Biolegend, London, UK). Anti-CD16-
APC (clone CB16), anti-CD57-e450 (clone TB01), Ki67-PerCP-eFluor710
(clone 20Raj1), anti-NKG2C-PE (clone 134591) (R&D systems), and anti-
FcεR1γ− FITC (rabbit polyclonal Ig) (Millipore, UK).
Statistics
Statistical analysis was performed using GraphPad Prism version 7.04
(GraphPad, California, USA.). Functional responses were compared using
Wilcoxon signed-rank test or one-way ANOVA mixed effects analysis with
correction for multiple comparisons (detailed in figure legends). Correla-
tion of two variables was determined using Pearson correlation analysis.
Significance levels are assigned as *p= 0.05, **p= 0.01, ***p= 0.001, and
****p= 0.0001 for all tests.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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